DaVita (NYSE:DVA) Issues FY24 Earnings Guidance

DaVita (NYSE:DVA) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $9.00-$9.80 for the period, compared to the consensus earnings per share estimate of $9.30.

DaVita Stock Down 5.5 %

Shares of DVA stock traded down $7.79 during mid-day trading on Friday, reaching $134.45. 2,541,405 shares of the company were exchanged, compared to its average volume of 628,593. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19. The business’s 50 day simple moving average is $133.71 and its 200 day simple moving average is $112.84. The company has a market capitalization of $11.79 billion, a P/E ratio of 15.28, a P/E/G ratio of 1.20 and a beta of 1.04. DaVita has a fifty-two week low of $71.51 and a fifty-two week high of $145.04.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 66.59% and a net margin of 6.61%. The business had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same period last year, the firm earned $1.58 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Research analysts predict that DaVita will post 9.49 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the subject of several recent research reports. Barclays began coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an equal weight rating and a $133.00 price target for the company. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. StockNews.com upgraded DaVita from a buy rating to a strong-buy rating in a research report on Thursday, April 25th. Truist Financial raised their target price on DaVita from $130.00 to $135.00 and gave the company a hold rating in a research report on Tuesday, February 20th. Finally, UBS Group boosted their price target on DaVita from $113.00 to $134.00 and gave the stock a buy rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of Moderate Buy and a consensus target price of $118.50.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares in the company, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other DaVita news, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares in the company, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Javier Rodriguez sold 67,603 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. In the last 90 days, insiders sold 134,540 shares of company stock valued at $16,551,071. Company insiders own 1.40% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.